Background and Purpose—Evidence from the real-world setting complements evidence
coming from randomized controlled trials. We aimed to summarize all available evidence …

Purpose The findings from the observational studies comparing the effectiveness and safety
of non–vitamin K antagonist oral anticoagulants (NOACs) versus vitamin K antagonists …

Background—The safety and effectiveness of non–vitamin K antagonist (VKA) oral
anticoagulants, dabigatran or rivaroxaban, were compared with VKA in anticoagulant-naive …

Background and Purpose—Limited real-world data exist comparing each non–vitamin K
antagonist oral anticoagulant (NOAC) to warfarin in patients with nonvalvular atrial …

Background & Aims There is controversy over whether use of non-vitamin K antagonist oral
anticoagulants (NOACs) associates with increased risk of major gastrointestinal bleeding …

The effectiveness and safety of rivaroxaban for stroke prevention in atrial fibrillation (SPAF)
demonstrated in ROCKET AF needs to be confirmed in daily care. To evaluate effectiveness …

Introduction and objectives To assess the effectiveness of direct oral anticoagulants vs
vitamin K antagonists in real-life patients with atrial fibrillation. Methods A systematic review …

Introduction Oral anticoagulants (OACs) prevent stroke in patients with atrial fibrillation (AF).
Several factors may cause OAC switching. Objectives To examine the phenomenon of OAC …

This article has been corrected. The original version (PDF) is appended to this article as a
Supplement. Background: Dabigatran (150 mg twice daily) has been associated with lower …

Background Patients with warfarin have a potential risk of warfarin-related nephropathy,
which could result in the discontinuation of anticoagulation therapy. The question of whether …